GlassScriptPhysician profile
Danish Qureshi
NPI 1093339343
$8,081.68
in general payments reported to CMS, 2019-2025
14 companies · $6,030 in 2025
The $6,030 reported for 2025 was more than what 92% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $906 · 2024: $1,145 · 2025: $6,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,328 · Food and Beverage: $3,060 · Travel and Lodging: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,328.00 |
| Food and Beverage | $3,060.07 |
| Travel and Lodging | $1,693.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $3,328.00 | 2025 | Rs-4i Plus With Intersperse |
| Medtronic, INC. | $2,389.66 | 2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Teva Pharmaceuticals USA, INC. | $501.33 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $450.19 | 2023-2024 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $304.88 | 2023-2024 | Abilify Asimtufii, Abilify Maintena |
| Tersera Therapeutics LLC | $190.34 | 2025 | Prialt |
| Bioxcel Therapeutics, INC. | $190.14 | 2023-2024 | Igalmi |
| Neurocrine Biosciences, INC. | $128.35 | 2024 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.01 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Nalu Medical, INC. | $122.00 | 2025 | Nalu Neurostimulation System |
| Janssen Pharmaceuticals, INC | $108.22 | 2024 | Invega Sustenna |
| Indivior INC. | $59.64 | 2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.92 | 2023-2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danish Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.